RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 09, 2025 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
January 06, 2025 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
RAPT Therapeutics Announces $150 Million Private Placement
December 23, 2024 07:10 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and...
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
December 23, 2024 07:00 ET
|
RAPT Therapeutics, Inc.
- RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on...
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
November 12, 2024 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and...
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
November 11, 2024 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
August 08, 2024 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and...
RAPT Therapeutics Reports First Quarter 2024 Financial Results
May 09, 2024 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and...
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
April 09, 2024 12:00 ET
|
RAPT Therapeutics, Inc.
- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% in subset of patients with PD-L1+ disease - Confirmed ORR of 22.2% in...
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 07, 2024 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and...